Arvinas (ARVN) Non-Current Debt (2017 - 2026)
Arvinas (ARVN) recorded quarterly Non-Current Debt of $300000.0 in Q1 2026, down 25.0% quarter-over-quarter from $400000.0 in Q4 2025, and down 40.0% on a YoY basis from $500000.0 in Q1 2025.
Arvinas (ARVN) Non-Current Debt (2017 - 2026) Analysis & Trends
Arvinas' Non-Current Debt history runs 10 years deep, the most recent figure standing at $300000.0 for Q1 2026.
- In Q1 2026, Non-Current Debt fell 40.0% year-over-year to $300000.0; the TTM figure through Mar 2026 stood at $300000.0 (down 40.0% YoY), while the FY2025 annual figure was $400000.0, down 33.33% from the prior year.
- Non-Current Debt was $300000.0 for Q1 2026 at Arvinas, down from $400000.0 in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $1.0 million in Q1 2022 to a low of $300000.0 in Q1 2026.
- Historically, Non-Current Debt has averaged $711764.7 across 5 years, with a median of $700000.0 in 2024.
- Biggest YoY gain for Non-Current Debt was 0.0% in 2022; the steepest drop was 50.0% in 2022.
- A 5-year view of Non-Current Debt shows it stood at $1.0 million in 2022, then dropped by 20.0% to $800000.0 in 2023, then decreased by 25.0% to $600000.0 in 2024, then sank by 33.33% to $400000.0 in 2025, then decreased by 25.0% to $300000.0 in 2026.
- The last three Non-Current Debt figures came in at $300000.0 (Q1 2026), $400000.0 (Q4 2025), and $400000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Arvinas | 492.16 Mn | -122.74 Mn | - | 300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Dec 31, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Sep 30, 2025 | 400,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Jun 30, 2025 | 500,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Sep 30, 2024 | 600,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Jun 30, 2024 | 700,000.00 |
| Mar 31, 2024 | 700,000.00 |
| Mar 31, 2024 | 700,000.00 |
| Dec 31, 2023 | 800,000.00 |
| Dec 31, 2023 | 800,000.00 |